Advertisement

Archives of Osteoporosis

, 13:121 | Cite as

Osteoporosis in postmenopausal women in this decade: a bibliometric assessment of current research and future hotspots

  • Yuanyu QiuEmail author
  • Wu Yang
  • Qijin Wang
  • Sijia Yan
  • Bo LiEmail author
  • Xiao ZhaiEmail author
Review Article

Abstract

Summary

Postmenopausal osteoporosis (PMOP) has already become a major public health problem. However, there was no bibliometric analysis estimating the evolutionary process of PMOP research.

Purpose

This study aimed to assess its scientific activity.

Methods

Publications on PMOP were retrieved from Science Citation Index-Expanded (SCI-E) of the Web of Science (WoS) from 2008 to 2018. VOSviewer software was used for data mining and visualization. The quantity of papers, number of citations, citation frequency per year, and H-index were assessed and compared among different countries, institutes, and researchers.

Results

A total of 11,142 papers were included and were cited 184,416 times. The USA contributed the most papers (3162), the most citations (83,270 times), and the highest H-index (115). Canada ranked first for the number of papers per million populations and per trillion GDP. Seven of the top ten funding agencies were industries. The key words were stratified into four clusters: cluster 1 (“basic research”), cluster 2 (“diagnosis”), cluster 3 (“treatment”), and cluster 4 (“others”). Average appearing years (AAY) of key words in cluster 1 were the largest compared to those in clusters 2 and 3. For hotspots, “miRNA” showed a relatively latest AAY of 2017.63, followed by “abaloparatide” and “adipokine”.

Conclusion

We concluded that the USA and Europe were the most productive regions on PMOP, with a high prevalence of articles supported by pharmaceutical companies. Key word focus gradually shifted from “diagnosis” to “treatment” and then to precision medicine orientated “basic research”. It is recommended to pay attention to potential research hotspots, such as “miRNA,” “abaloparatide,” and “adipokine”.

Keywords

Bibliometric Citation H-index Postmenopausal osteoporosis Hotspots 

Abbreviations

PMOP

postmenopausal osteoporosis

SCI-E

science citation index-expanded

WoS

web of science

GDP

gross domestic product

IF

impact factor

AAY

average appearing years

RCT

randomized controlled trial

BMD

bone mineral density

FRAX

fracture risk assessment tool

Notes

Authors’ contributions

X, Z and B, L: conceived and designed the experiments. YY, Q, and W, Y: performed the experiments: QJ, W analyzed the data. YY, Q and SJ, Y: wrote the paper. All authors read and approved the final manuscript.

Funding

This study was supported by Foundation of Changhai Hospital (CH201717); National Natural Science Foundation of China (81701199).

Compliance with ethical standards

Conflict of interest

None.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable since the manuscript is entirely original; the tables and figures presented are original for this article and have neither been published nor are currently under consideration for publication by any other journal.

Supplementary material

11657_2018_534_MOESM1_ESM.xls (71 kb)
ESM 1 (XLS 71 kb)
11657_2018_534_MOESM2_ESM.docx (67 kb)
ESM 2 (DOCX 66 kb)

References

  1. 1.
    Kanis JA, EV MC, Johansson H, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, Osteoarthritis, the Committee of Scientific Advisors of the International Osteoporosis F (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57CrossRefGoogle Scholar
  2. 2.
    Black DM, Rosen CJ (2016) Clinical Practice Postmenopausal Osteoporosis. N Engl J Med 374:254–262CrossRefGoogle Scholar
  3. 3.
    Imai T, Tanaka S, Kawakami K, Miyazaki T, Hagino H, Shiraki M, Group ATR (2017) Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial. Osteoporos Int 28:1893–1901CrossRefGoogle Scholar
  4. 4.
    Biglu MH, Ghavami M, Biglu S (2014) Authorship, institutional and citation metrics for publications on postmenopausal osteoporosis. Osteoporos Int 25:1337–1343CrossRefGoogle Scholar
  5. 5.
    Chen X, Zhi X, Cao L, Weng W, Pan P, Hu H, Liu C, Zhao Q, Zhou Q, Cui J, Su J (2017) Matrine derivate MASM uncovers a novel function for ribosomal protein S5 in osteoclastogenesis and postmenopausal osteoporosis. Cell Death Dis 8:e3037CrossRefGoogle Scholar
  6. 6.
    Si L, Winzenberg TM, Chen M, Jiang Q, Neil A, Palmer AJ (2016) Screening for osteoporosis in Chinese post-menopausal women: a health economic modelling study. Osteoporos Int 27:2259–2269CrossRefGoogle Scholar
  7. 7.
    Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NF, McCloskey EV, Walsh JS, Eastell R (2016) Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporos Int 27:21–31CrossRefGoogle Scholar
  8. 8.
    Glanville J, Kendrick T, McNally R, Campbell J, Hobbs FD (2011) Research output on primary care in Australia, Canada, Germany, the Netherlands, the United Kingdom, and the United States: bibliometric analysis. Bmj 342:d1028CrossRefGoogle Scholar
  9. 9.
    Bornmann L, Leydesdorff L (2014) Scientometrics in a changing research landscape: bibliometrics has become an integral part of research quality evaluation and has been changing the practice of research. EMBO Rep 15:1228–1232CrossRefGoogle Scholar
  10. 10.
    Avcu G, Sahbudak Bal Z, Duyu M, Akkus E, Karapinar B, Vardar F (2015) Thanks to trauma: a delayed diagnosis of Pott disease. Pediatr Emerg Care 31:e17–e18CrossRefGoogle Scholar
  11. 11.
    Zhao J, Yu G, Cai M, Lei X, Yang Y, Wang Q, Zhai X (2018) Bibliometric analysis of global scientific activity on umbilical cord mesenchymal stem cells: a swiftly expanding and shifting focus. Stem Cell Res Ther 9:32CrossRefGoogle Scholar
  12. 12.
    Gao Y, Wang Y, Zhai X, He Y, Chen R, Zhou J, Li M, Wang Q (2017) Publication trends of research on diabetes mellitus and T cells (1997-2016): a 20-year bibliometric study. PLoS One 12:e0184869CrossRefGoogle Scholar
  13. 13.
    Yiran W, Qijin W, Xianzhao W, et al. (2017) Global scientific trends on exosome research during 2007-2016: a bibliometric analysis. OncotargetGoogle Scholar
  14. 14.
    Wang Y, Wang Q, Zhu R, Yang C, Chen Z, Bai Y, Li M, Zhai X (2016) Trends of spinal tuberculosis research (1994-2015): a bibliometric study. Medicine 95:e4923CrossRefGoogle Scholar
  15. 15.
    Sweileh WM (2017) Bibliometric analysis of literature on toxic epidermal necrolysis and Stevens-Johnson syndrome: 1940 - 2015. Orphanet J Rare Dis 12:14CrossRefGoogle Scholar
  16. 16.
    Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchina E, White J, Gross SS, Ma Y, Varticovski L, Melnick A, Chiosis G (2009) Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A 106:8368–8373CrossRefGoogle Scholar
  17. 17.
    Rakha EA, Ellis IO (2009) Triple-negative/basal-like breast cancer: review. Pathology 41:40–47CrossRefGoogle Scholar
  18. 18.
    Synnestvedt MB, Chen C, Holmes JH (2005) CiteSpace II: visualization and knowledge discovery in bibliographic databases. AMIA Annual Symposium proceedings / AMIA Symposium AMIA Symposium 724–728Google Scholar
  19. 19.
    Khalil GM, Gotway Crawford CA (2015) A bibliometric analysis of U.S.-based research on the behavioral risk factor surveillance system. Am J Prev Med 48:50–57CrossRefGoogle Scholar
  20. 20.
    Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765CrossRefGoogle Scholar
  21. 21.
    Kanis JA, Cooper C, Rizzoli R, Reginster JY (2018) Review of the guideline of the American College of Physicians on the treatment of osteoporosis. Osteoporos Int 29:1505–1510CrossRefGoogle Scholar
  22. 22.
    Hiligsmann M, Evers SM, Ben Sedrine W, Kanis JA, Ramaekers B, Reginster JY, Silverman S, Wyers CE, Boonen A (2015) A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. PharmacoEconomics 33:205–224CrossRefGoogle Scholar
  23. 23.
    Reginster JY, Hattersley G, Williams GC, Hu MY, Fitzpatrick LA, Lewiecki EM (2018) Abaloparatide is an effective treatment option for postmenopausal osteoporosis: review of the number needed to treat compared with Teriparatide. Calcif Tissue Int 103:540–545CrossRefGoogle Scholar
  24. 24.
    Tijssen RJ, Winnink J (2016) Twenty-first century macro-trends in the institutional fabric of science: bibliometric monitoring and analysis. Scientometrics 109:2181–2194CrossRefGoogle Scholar
  25. 25.
    Jin Y, Cui Z, Li X, Jin X, Peng J (2017) Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer. Oncotarget 8:26090–26099PubMedPubMedCentralGoogle Scholar
  26. 26.
    Cerreta F, Eichler HG, Rasi G (2012) Drug policy for an aging population--the European medicines Agency's geriatric medicines strategy. N Engl J Med 367:1972–1974CrossRefGoogle Scholar
  27. 27.
    Zhang L, Pang Y, Shi Y, Xu M, Xu X, Zhang J, Ji L, Zhao D (2015) Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. Menopause 22:1021–1025CrossRefGoogle Scholar
  28. 28.
    Kim K, Svedbom A, Luo X, Sutradhar S, Kanis JA (2014) Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm. Osteoporos Int 25:325–337CrossRefGoogle Scholar
  29. 29.
    Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwiński E, Krieg MA, Man Z, Mellström D, Radominski SC, Reginster JY, Resch H, Ivorra JAR, Roux C, Vittinghoff E, Austin M, Daizadeh N, Bradley MN, Grauer A, Cummings SR, Bone HG (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27:694–701CrossRefGoogle Scholar
  30. 30.
    Papapoulos S, Lippuner K, Roux C, Lin CJF, Kendler DL, Lewiecki EM, Brandi ML, Czerwiński E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster JY, Jensen S, Daizadeh NS, Wang A, Gavin M, Libanati C, Wagman RB, Bone HG (2015) The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension study. Osteoporos Int 26:2773–2783CrossRefGoogle Scholar
  31. 31.
    Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532–1543CrossRefGoogle Scholar
  32. 32.
    Liu Y, Cao Y, Zhang S, Zhang W, Zhang B, Tang Q, Li Z, Wu J (2018) Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials. Climacteric 21:189–195CrossRefGoogle Scholar
  33. 33.
    de Villiers TJ, Chines AA, Palacios S, Lips P, Sawicki AZ, Levine AB, Codreanu C, Kelepouris N, Brown JP (2011) Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 22:567–576CrossRefGoogle Scholar
  34. 34.
    Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjaerg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD, Bazedoxifene Study G (2012) Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 23:351–363CrossRefGoogle Scholar
  35. 35.
    Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie SA, Neer RM, Leder BZ (2013) Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 382:50–56CrossRefGoogle Scholar
  36. 36.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S (2011) Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 26:503–511CrossRefGoogle Scholar
  37. 37.
    Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, Audran M, Barker C, Anastasilakis AD, Fraser WD, Nickelsen T, EUROFORS Investigators (2008) Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23:1591–1600CrossRefGoogle Scholar
  38. 38.
    Doyle N, Varela A, Haile S, Guldberg R, Kostenuik PJ, Ominsky MS, Smith SY, Hattersley G (2018) Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption. Osteoporos Int 29:685–697CrossRefGoogle Scholar
  39. 39.
    Jin D, Wu X, Yu H, Jiang L, Zhou P, Yao X, Meng J, Wang L, Zhang M, Zhang Y (2018) Systematic analysis of lncRNAs, mRNAs, circRNAs and miRNAs in patients with postmenopausal osteoporosis. Am J Transl Res 10:1498–1510PubMedPubMedCentralGoogle Scholar
  40. 40.
    Li H, Wang Z, Fu Q, Zhang J (2014) Plasma miRNA levels correlate with sensitivity to bone mineral density in postmenopausal osteoporosis patients. Biomarkers 19:553–556CrossRefGoogle Scholar
  41. 41.
    Xiong K, Wu T, Fan Q, Chen L, Yan M (2017) Novel reduced graphene oxide/zinc silicate/calcium silicate Electroconductive biocomposite for stimulating osteoporotic bone regeneration. ACS Appl Mater Interfaces 9:44356–44368CrossRefGoogle Scholar
  42. 42.
    Kochetkova EA, Ugai LG, Maistrovskaia YV, Nevzorova VA (2017) Adipokines: a possible contribution to vascular and bone remodeling in idiopathic pulmonary arterial hypertension. Calcif Tissue Int 100:325–331CrossRefGoogle Scholar
  43. 43.
    Moradi S, Mirzaei K, Abdurahman AA, Keshavarz SA (2017) Adipokines may mediate the relationship between resting metabolic rates and bone mineral densities in obese women. Osteoporos Int 28:1619–1629CrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2018

Authors and Affiliations

  1. 1.Department of Gynecology and ObstetricsThe Affiliated Jiangyin Hospital of Southeast UniversityJiangyinChina
  2. 2.Department of OrthopedicsThe Affiliated Jiangyin Hospital of Southeast UniversityJiangyinChina
  3. 3.Department of Endocrinology, Changhai HospitalSecond Military Medical UniversityShanghaiChina
  4. 4.Department of Orthopedics, Changhai HospitalSecond Military Medical UniversityShanghaiChina

Personalised recommendations